Friday, Matinas BioPharma Holdings Inc (NYSE:MTNB) announced a complete clinical response in three patients with invasive fusarium infection following treatment with MAT2203, Matinas’ oral formulation of antifungal amphotericin B.
All three patients were enrolled in the company’s Compassionate/Expanded Use Access Program.
A 40-year-old female patient with extensive burns on more than 34% of her body developed complications of a urinary tract infection, ventilator-associated pneumonia, and C. difficile colitis.
Treatment with IV-amphotericin B led to nephrotoxicity, and her fusarium infection showed resistance to all other antifungals.
She was transitioned to oral MAT2203 for two weeks, which led to the clinical resolution of her fungal infection.
A 48-year-old female renal ...